INDOLEALKYL DERIVATIVES OF BENZODIOXANMETHYLAMINE AS 5-HT1A RECEPTOR LIGANDS
    2.
    发明公开
    INDOLEALKYL DERIVATIVES OF BENZODIOXANMETHYLAMINE AS 5-HT1A RECEPTOR LIGANDS 失效
    作为5-HT1A受体配体的苯并二恶烷甲胺的吲哚乙酰基衍生物

    公开(公告)号:EP0861248A1

    公开(公告)日:1998-09-02

    申请号:EP96937782.0

    申请日:1996-10-29

    IPC分类号: A61K C07D A61K31 A61P25 C07D405 C07D493

    CPC分类号: C07D493/04 C07D405/12

    摘要: The compounds of formula (I), wherein R?1, R4 and R5¿ are, independently, hydrogen, alkyl, alkoxy, aralkoxy, alkanoyloxy, hydroxy, halo, trifluoromethyl, amino, mono- or di-alkylamino, alkanamido, or alkanesulfonamido; or, R1 is defined as above and R?4 and R5¿, taken together, are ortho substituted methylenedioxy, ethylenedioxy, or propylenedioxy; R?2 and R3¿ are, independently, hydrogen or alkyl; n is 3 or 4; or pharmaceutically acceptable salts thereof, are useful in the treatment of depression and related disorders.

    摘要翻译: 其中R 1,R 4和R 5'独立地为氢,烷基,烷氧基,芳烷氧基,烷酰氧基,羟基,卤素,三氟甲基,氨基,单烷基氨基或二烷基氨基,烷酰氨基或烷基磺酰氨基 ; 或者R1如上所定义,并且R4和R5一起为邻位取代的亚甲二氧基,亚乙二氧基或亚丙基二氧基; R 2和R 3独立地是氢或烷基; n是3或4; 或其药学上可接受的盐可用于治疗抑郁症和相关病症。

    AZAHETEROCYCLYMETHYL DERIVATIVES OF 2,3,8,9-TETRAHYDRO-7H-1,4-DIOXINO 2,3-e]INDOL-8-ONE
    4.
    发明公开
    AZAHETEROCYCLYMETHYL DERIVATIVES OF 2,3,8,9-TETRAHYDRO-7H-1,4-DIOXINO 2,3-e]INDOL-8-ONE 失效
    二异丙氧基甲基衍生物腙2,3,8,9-四氢-7H- 1,4-二氧杂环己烯并[2,3-E]吲哚-8-酮

    公开(公告)号:EP0932609A1

    公开(公告)日:1999-08-04

    申请号:EP97910866.0

    申请日:1997-10-10

    发明人: STACK, Gary, Paul

    IPC分类号: A61K31 A61P25 A61P43 C07D491 C07D519

    CPC分类号: C07D491/04

    摘要: The compounds of formula (I) wherein X is H2 or O; R1 is hydrogen, hydroxy, halo, trifluoromethyl, trifluoromethoxy, alkyl, alkoxy, aralkoxy, alkanoyloxy, amino, mono- or di-alkylamino, alkanamido or alkanesulfonamido; Z is defined by formula (II), (III) or (IV) wherein R2 is hydrogen, alkyl, cycloalkyl, phenyl optionally substituted with R1 as defined above, φ-phenylalkyl or φ-diphenylalkyl, in which the phenyl ring is optionally substituted with R1 as defined above, or R2 is naphthyl, indolyl, indazolyl, thienyl, pyridinyl, pyrimidinyl, quinolinyl, benzoisothiazolyl or benzisoxazolyl, each optionally substituted with R1 as defined above; R3 is hydrogen and R4 is hydrogen, 1-benzimidazolyl-2-one, indolyl, benzoisothiazolyl or benzisoxazolyl, each optionally substituted with R1 as defined above, or R4 is -Y-Ar, in which Y is C=O, CHOH, or (CH¿2?)m, wherein m is 0 to 4, and Ar is phenyl, optionally substituted with R?1¿ as defined above; or R?3 and R4¿, taken together with the carbon atom to which they are attached form (V) or (VI) in which R5 is hydrogen and R6 is phenyl, naphthyl, thienyl, indolyl, benzoisothiazolyl or benzisoxazolyl, each optionally substituted with R1 as defined above; or R?5 and R6¿, taken together with the carbon atoms to which they are attached complete a benzene ring optionally substituted with R1; or a pharmaceutically acceptable salt thereof; are useful for the treatment of brain dopamine dysregulation.